| | | | | Several European countries have started testing a technology platform that will allow national coronavirus tracing apps to 'talk' to one another to better tackle the pandemic, the European Commission said on Monday. | | |
| | | As the coronavirus pandemic spreads deeper into America’s small towns and rural outposts, Dr. Tallulah Holmstrom has seen familiar faces fill her intensive-care unit in Camden, South Carolina. | | |
| | | Merck & Co Inc said on Monday it would buy $1 billion worth of equity stake in Seattle Genetics's common stock. | | |
| | | Singapore began handing out pocket-sized coronavirus contact-tracing devices to residents on Monday, part of a planned nationwide rollout to help the city-state safely reopen its economy. | | |
| | | Eli Lilly and Co said on Monday its rheumatoid arthritis drug baricitinib shortened the time taken to recover from COVID-19 in hospitalized patients when taken in combination with Gilead Sciences Inc's antiviral remdesivir. | | |
| | | The world's largest randomised trial of potential medicines for COVID-19 is to add Regeneron's experimental antiviral antibody cocktail REGN-COV2 to the drugs it is testing in patients hospitalised with the disease. | | |
| | | AstraZeneca's British clinical trials of its COVID-19 vaccine, one of the most advanced in development, resumed on Monday, according to the European clinical trials database EudraCT. | | |
| | | Here's what you need to know about the coronavirus right now: | | |
| | | India's parliament met for the first time in six months on Monday, as novel coronavirus cases across the country rose by more than 90,000 in the space of a day and the total number of infections neared 5 million. | | |
| | | Global coronavirus cases marked a record one-day increase, with many countries facing a second wave of infections, while a pandemic preparedness panel slammed the collective failure of political leaders to heed warnings and prepare for a crisis. | | |
| | | Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday. | | |
|
| |
